Clinical Trial Assessing the Value of an Antibiotic Protocol Guided by Serum Procalcitonin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Intensive Care

Not Applicable

• Conditions: Chronic Obstructive Pulmonary Disease

• Registration Number: NCT02521636
• Lead Sponsor: University Hospital, Caen

Brief Summary

Investigators propose to conduct a prospective, randomized, controlled, multicenter assessing the interests of an antibiotic protocol guided by serum procalcitonin (PCT) on morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD) hospitalized in intensive care unit (ICU) for acute exacerbation with or without associated pneumonia. The main objective is to show in patients hospitalized in intensive care for acute exacerbation of COPD with or without pneumonia, safety, defined as a lack of difference in mortality at 3 months, an antibiotic strategy guided by the PCT in the ICU.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-10
• Status Verified: 2015-08
• Study First Submitted: 2015-08-05
• Study First Submitted QC: 2015-08-10
• Last Update Submitted: 2015-08-10
• Study First Posted: 2015-08-13
• Last Update Posted: 2015-08-13
• Primary Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• patients over 18 years
• Documented or suspected clinically COPD according to the criteria of GOLD
• In acute exacerbation
• Suspect of lower respiratory tract infection
• With or without pulmonary criteria defined as the presence of a radiological infiltrates consistent with an infectious site and associated with one or more of the following items: dyspnea, cough, sputum, fever above 38 ° C, fireplace clinical auscultation, higher leukocytosis at 10,000 / mm³ or leukopenia below 4000 / mm³
• Admitted to the hospital for less than 48 hours
• ICU Admission
• Informed Consent signed by the patient or his representative

Exclusion Criteria

• Other than acute exacerbation etiology with or without pulmonary disease as suspected cause of ICU admission
• Patient immunocompromised neutropenia neutrophil count below 500 / mm³ secondary to chemotherapy, corticosteroids greater than 0.5 mg / kg / day for more than 10 days, HIV seropositivity
• Severe Acute Asthma
• Moribund patient or a disease with an estimated survival time of less than three months
• Therapeutic limitation Existence
• minor patient or under guardianship or custody
• Pregnant woman
• Refusal to participate in the study
• The inclusion of the subject in another biomedical research protocol in progress or for less than 30 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
mortality	3 month

Trial Locations

Locations (1)

Medical Intensive Care Unit, CHU Caen; 🇫🇷 Caen, France